Search Results - "Boque, Concepción"

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial by Cortes, Jorge E, Saglio, Giuseppe, Kantarjian, Hagop M, Baccarani, Michele, Mayer, Jiří, Boqué, Concepción, Shah, Neil P, Chuah, Charles, Casanova, Luis, Bradley-Garelik, Brigid, Manos, George, Hochhaus, Andreas

“…We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial,…”
Get full text

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia by Kantarjian, Hagop, Shah, Neil P, Shah, Sandip, Hochhaus, Andreas, Cortes, Jorge, Ayala, Manuel, Moiraghi, Beatriz, Shen, Zhixiang, Mayer, Jiri, Pasquini, Ricardo, Nakamae, Hirohisa, Huguet, Françoise, Boqué, Concepción, Chuah, Charles, Bleickardt, Eric, Bradley-Garelik, M. Brigid, Zhu, Chao, Szatrowski, Ted, Shapiro, David, Baccarani, Michele

“…The treatment of chronic myeloid leukemia (CML) achieved a great leap forward with the development of imatinib, a BCR-ABL kinase inhibitor. Alterations in the…”
Get full text

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) by Jabbour, Elias, Kantarjian, Hagop M., Saglio, Giuseppe, Steegmann, Juan Luis, Shah, Neil P., Boqué, Concepción, Chuah, Charles, Pavlovsky, Carolina, Mayer, Jiří, Cortes, Jorge, Baccarani, Michele, Kim, Dong-Wook, Bradley-Garelik, M. Brigid, Mohamed, Hesham, Wildgust, Mark, Hochhaus, Andreas

“…This analysis explores the impact of early cytogenetic and molecular responses on the outcomes of patients with chronic myeloid leukemia in chronic phase…”
Get full text

Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations by Boqué, Concepción, Sánchez-Ramón, Silvia, Córdoba, Raúl, Moreno, Carol, Cabezudo, Elena

“…A Delphi-based survey was designed to assess the opinions of clinical hematologists (n = 17) and clinical immunologists (n = 18) from across Spain on secondary…”
Get full text

A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera by Hernández-Boluda, Juan-Carlos, Pereira, Arturo, Cervantes, Francisco, Alvarez-Larrán, Alberto, Collado, María, Such, Esperanza, Arilla, M. Jesús, Boqué, Concepción, Xicoy, Blanca, Maffioli, Margherita, Bellosillo, Beatriz, Marugán, Isabel, Amat, Paula, Besses, Carles, Guillem, Vicent

“…Patients with essential thrombocythemia (ET) and polycythemia vera (PV) have an increased incidence of acute myeloid leukemia and new nonhematologic…”
Get full text

The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis by Hernández-Boluda, Juan-Carlos, Pereira, Arturo, Gómez, Montse, Boqué, Concepción, Ferrer-Marín, Francisca, Raya, José-María, García-Gutiérrez, Valentín, Kerguelen, Ana, Xicoy, Blanca, Barba, Pere, Martínez, Jesús, Luño, Elisa, Alvarez-Larrán, Alberto, Martínez-López, Joaquín, Arbelo, Elisa, Besses, Carles

Get full text

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea by Alvarez-Larrán, Alberto, Pérez-Encinas, Manuel, Ferrer-Marín, Francisca, Hernández-Boluda, Juan Carlos, Ramírez, María José, Martínez-López, Joaquín, Magro, Elena, Cruz, Yasmina, Mata, María Isabel, Aragües, Pilar, Fox, María Laura, Cuevas, Beatriz, Montesdeoca, Sara, Hernández-Rivas, José Angel, García-Gutiérrez, Valentín, Gómez-Casares, María Teresa, Steegmann, Juan Luis, Durán, María Antonia, Gómez, Montse, Kerguelen, Ana, Bárez, Abelardo, García, Mari Carmen, Boqué, Concepción, Raya, José María, Martínez, Clara, Albors, Manuel, García, Francesc, Burgaleta, Carmen, Besses, Carlos

“…Hematocrit control below 45% is associated with a lower rate of thrombosis in polycythemia vera. In patients receiving hydroxyurea, this target can be achieved…”
Get full text

PB2699: CONSENSUS FROM AN EXPERT PANEL ON THE CURRENT MANAGEMENT OF SECONDARY IMMUNODEFICIENCY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN SPAIN by Boqué, Concepción, Sánchez‐Ramón, Silvia, Cordoba, Raul, Moreno, Carol, Perez, Elena Cabezudo

Get full text

Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis by Zamora, Lurdes, Xicoy, Blanca, Cabezón, Marta, Fernandez, Cristalina, Marcé, Silvia, Velez, Patricia, Xandri, Marisol, Gallardo, David, Millá, Fuensanta, Feliu, Evarist, Boqué, Concepción

Get full text

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients by Hernández-Boluda, Juan Carlos, Pereira, Arturo, Pastor-Galán, Irene, Alvarez-Larrán, Alberto, Savchuk, Alisa, Puerta, José Manuel, Sánchez-Pina, José María, Collado, Rosa, Díaz-González, Alvaro, Angona, Anna, Sagüés, Miguel, García-Gutiérrez, Valentín, Boqué, Concepción, Osorio, Santiago, Vallansot, Rolando, Palomera, Luis, Mendizábal, Arantxa, Casado, Luis Felipe, Pérez-Encinas, Manuel, Pérez-López, Raúl, Ferrer-Marín, Francisca, Sánchez-Guijo, Fermín, García, Carmen, Heras, Natalia de las, López-Lorenzo, José Luis, Cervantes, Francisco, Steegmann, Juan Luis

“…Over half of chronic myeloid leukemia (CML) patients in deep molecular response do not lose the major molecular response (MMR) after stopping treatment with…”
Get full text

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients by Estrada, Natalia, Xicoy, Blanca, Beier, Fabian, Garcia, Olga, Morales, Cristian, Boqué, Concepción, Sagüés, Miguel, Ventura Ferreira, Mónica S., Vallansot, Rolando, Marcé, Sílvia, Cabezón, Marta, Brümmendorf, Tim H., Zamora, Lurdes

“…Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the…”
Get full text

Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program by García‐Gutiérrez, Valentín, Martinez‐Trillos, Alejandra, Lopez Lorenzo, Jose Luis, Bautista, Guiomar, Martin Mateos, Maria Luisa, Alvarez‐Larrán, Alberto, Iglesias Pérez, Ana, Romo Collado, Andrés, Fernandez, Angeles, Portero, Angeles, Cuevas, Beatriz, Ruiz, Concepción, Romero, Esperanza, Ortega, Fernando, Mata, Isabel, Tallón, José, García Garay, Maria del Carmen, Ramirez Sánchez, María José, de las Heras, Natalia, Giraldo, Pilar, Bobillo, Sabela, Guinea, José María, Deben, Guillermo, Valencia, Sandra, Sebrango, Ana, Boqué, Concepción, Maestro, Begoña, Steegmann, Juan Luis

“…The role of bosutinib as rescue treatment of Philadelphia chromosome‐positive chronic myeloid leukemia (CML) patients after failing three previous tyrosine…”
Get full text

Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients by Estrada, Natalia, Zamora, Lurdes, Ferrer-Marín, Francisca, Palomo, Laura, García, Olga, Vélez, Patricia, De la Fuente, Iris, Sagüés, Miguel, Cabezón, Marta, Cortés, Montserrat, Vallansot, Rolando Omar, Senín-Magán, María Alicia, Boqué, Concepción, Xicoy, Blanca

“…Imatinib is the most common first-line tyrosine kinase inhibitor (TKI) used to treat chronic-phase chronic myeloid leukemia (CP-CML). However, only a…”
Get full text

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib by Marcé, Sílvia, Xicoy, Blanca, García, Olga, Cabezón, Marta, Estrada, Natalia, Vélez, Patricia, Boqué, Concepción, Sagüés, Miguel, Angona, Anna, Teruel-Montoya, Raúl, Ferrer-Marín, Francisca, Amat, Paula, Hernández-Boluda, Juan, Ibarra, Mariana, Anguita, Eduardo, Cortés, Montserrat, Fernández-Ruiz, Andrés, Fontanals, Sandra, Zamora, Lurdes

“…The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase…”
Get full text

Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients by Hernandez Boluda, Juan Carlos, Pereira, Arturo, Pastor-Galán, Irene, Alvarez-Larrán, Alberto, Savchuk, Alisa, Puerta, Jose Manuel, Sanchez, Jose M., Collado, Rosa, Díaz, Álvaro, Angona, Anna, Sagüés, Miguel, García Gutiérrez, Valentín, Boque, Concepcion, Gómez-Centurión, Ignacio, Vallansot, Rolando, Palomera, Luis, Mendizábal, Arantxa, Casado, Luis Felipe, Pérez-Encinas, Manuel, Perez Lopez, Raul, Ferrer Marin, Francisca, Sanchez-Guijo, Fermin, Garcia-Hernandez, Carmen, de las Heras, Natalia, Lopez Lorenzo, Jose Luiz, Cervantes, Francisco, Steegmann, Juan Luis

“…Introduction: Over half of patients with chronic myeloid leukemia (CML) in sustained deep molecular remission do not lose the major molecular response (MMR)…”
Get full text

Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC study by Boqué, Concepción, Abad, María Reyes, Agustín, María José, García-Goñi, Manuel, Moreno, Carolina, Gabás-Rivera, Clara, Granados, Enrique, Castro-Gómez, Antonio, Pardo, Carlos, Lizán, Luis

“…To explore the preferences of Spanish healthcare professionals (haematologists and hospital pharmacists) for the treatment selection of active Chronic…”
Get full text

Highly variable mutational profile of ASXL1 in myelofibrosis by Sorigué, Marc, Ribera, Josep-Maria, García, Olga, Cabezón, Marta, Vélez, Patricia, Marcé, Silvia, Xicoy, Blanca, Fernández, Cristalina, Buch, Joan, Cortes, Montserrat, Plensa, Esther, Gallardo, David, Boqué, Concepción, Feliu, Evarist, Zamora, Lurdes

“…Objective Somatic mutations in ASXL1 seem to have a negative prognostic impact in patients with several myeloid neoplasms, including myelofibrosis (MF). The…”
Get full text

Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data by Saglio, Giuseppe, Kantarjian, Hagop M., Shah, Neil, Jabbour, Elias J., Quintas-Cardama, Alfonso, Steegmann, Juan Luis, Boqué, Concepción, Chuah, Charles, Pavlovsky, Carolina, Mayer, Jiří, Ukropec, Jon, Wildgust, Mark, Hochhaus, Andreas

“…Abstract 1675 In the randomized phase 3 DASISION trial in patients (pts) with newly diagnosed CML-CP, dasatinib 100 mg once daily (QD) demonstrated improved…”
Get full text

Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study by Sánchez-Guijo, Fermin M, Durán, Soledad, Galende, Josefina, Boqué, Concepción, Nieto, José B, Balanzat, Josep, Gracia, Antonio, García, Isabel, Avellaneda-Molina, Carmen, Moreno, María-Victoria, Luño-Fernandez, Elisa, Hermosilla, Mar, Sanchez-Varela, José Manuel, Dios, Ana, López-Garrido, Pilar, Giraldo, Pilar, Bargay, Joan, Domingo, José María, Soler, Alfonso, Salinas, Ramón, del Cañizo, Maria-Consuelo

“…Abstract Imatinib mesylate (IM) is the treatment of choice in patients with newly diagnosed chronic myeloid leukemia (CML), irrespectively of their age…”
Get full text

Cadherin-13, a Mediator of Calcium-Dependent Cell-Cell Adhesion, Is Silenced by Methylation in Chronic Myeloid Leukemia and Correlates With Pretreatment Risk Profile and Cytogenetic Response to Interferon Alfa by ROMAN-GOMEZ, Jose, CASTILLEJO, Juan A, TORRES, Antonio, JIMENEZ, Antonio, CERVANTES, Francisco, BOQUE, Concepcion, HERMOSIN, Lourdes, LEON, Angel, GRANENA, Albert, COLOMER, Dolors, HEINIGER, Anabel

“…Cadherin-13 (CDH13) is a newly characterized cadherin molecule responsible for selective cell recognition and adhesion, the expression of which is decreased by…”
Get full text